CAY10678 (Synonyms:mPGES1-IN-7)
目录号 : KCM10888 CAS No. : 1268709-57-4 纯度 : ≥98%
Microsomal prostaglandin E synthase-1 (mPGES-1) converts the COX product PGH into the biologically active PGE Like COX-2, the expression of mPGES-1 is induced in response to pro-inflammatory mediators, including LPS, IL-1β, and TNF-α. CAY10678 is a benzoimidazole that potently inhibits human and rat recombinant mPGES-1 (IC = 0.09 and 0.9 µM, respectively). It has minimal effects on COX-1, COX-2, PGIS, and hematopoietic PGDS at 50 μM but reduces lipocalin-type PGDS activity by 60% at this concentration. CAY10678 dose-dependently blocks PGE synthesis in isolated cells and whole blood treated with LPS or IL-1β. It also dose-dependently reduces PGE synthesis and cell recruitment during inflammation in mice.
规格 价格 是否有货 数量
10 mM * 1 mL in DMSO
In-stock
1mg
In-stock
5mg
In-stock
10mg
In-stock

Other Forms of Rapamycin:

KKL Med 的所有产品和服务仅用于科学研究,不能被用于人体,兽医,我们也不向个人提供产品和服务。
生物活性

CAY10678 is a benzimidazole-based mPGES-1 inhibitor that also inhibits adipophysin PGD synthase (I-PGDS) (5 μM, IR=60 %). CAY10678 reduces PGE2 production and tends to reduce levels of other prostaglandins. CAY10678 effectively inhibits acute inflammation in an air sac model stimulated by Carrageenan in mice[1].

IC50&Target

IC50: 0.9 μM (recombinant human mPGES-1), 0.09 μM (recombinant rat mPGES-1)[1]; lipocalin-type PGD synthase (I-PGDS)[1]

体外研究

CAY10678 (0.64-80 μ M; 24 h) can reduce PGE2 production induced by LPS (10 ng/mL) stimulation in A549 cells, mouse macrophages, and blood [1].

CAY10678 inhibits PGE2 synthesis in a concentration dependent manner, leading to the diversion of PGH2 to the prostacyclin pathway [1]

体内研究

CAY10678 (10-100 mg/kg; ip; single dose) effectively inhibits the overall synthesis of prostaglandins and reduces cell migration in a mouse model of balloon inflammation induced by 1% λ - Carrageenan [1].

 

Animal Model: 1% Carrageenan stimulated mouse air pouch model
Dosage: 10, 50, 100 mg/kg
Administration: ip; single dose after modeling: use 3 mL of sterile-filtered air was injected sub-cutaneously into the interscapular region of mice; triggered in the pouch 24 h later by the injection of a 1 ml solution of λ-carrageenan (1%) in saline.
Result: Had no effect on inflammatory exudate volume but dose-dependently reduced cell migration.
Resulted in a decrease in PGE2 synthesis, it does not affect changes in other prostaglandin levels, but leads to an overall downregulation of prostaglandin synthesis.
 
分子式
C23H34N4O
分子量
382.54
CAS号
1268709-57-4
运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
溶解性数据
In Vitro:

DMSO : 31.25 mg/mL (81.69 mM; Need ultrasonic)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 2.6141 mL 13.0705 mL 26.1411 mL
5 mM 0.5228 mL 2.6141 mL 5.2282 mL
10 mM 0.2614 mL 1.3071 mL 2.6141 mL
*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂: 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% saline

    Solubility: ≥ 2 mg/mL (5.23 mM); Clear solution

    此方案可获得 ≥ 2 mg/mL (5.23 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 20.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

[1]. Leclerc P, et al. Characterization of a human and murine mPGES-1 inhibitor and comparison to mPGES-1 genetic deletion in mouse models of inflammation. Prostaglandins Other Lipid Mediat. 2013 Dec;107:26-34. 

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
动物实验计算换算器
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度 mg/ml;

DMSO母液配制方法 mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。

配置后的溶液总体积

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。